NewsAI-assisted
China Accepts Telix NDA For Illuccix PSMA-PET Prostate Cancer Imaging
Telix secures NDA acceptance in China for Illuccix, marking a major step toward expanding PSMA-PET imaging in prostate cancer care.
By Vaibhavi M.
Subject Matter Expert · Pharma Now
Jan 20, 20262 min read
AI-assisted reporting
Reviewed by Vaibhavi M., Subject Matter Expert · Pharma Now
Telix Pharmaceuticals has announced that China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the New Drug Application (NDA) for TLX591-Px (Illuccix®), a kit used to prepare ^68Ga-PSMA-11 for prostate cancer imaging. Illuccix is Telix’s lead diagnostic imaging agent for prostate cancer and represents a key step in expanding access to PSMA-PET imaging in China.
TopicsNews
Written by
Vaibhavi M.
Subject Matter Expert · Pharma Now
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Discussion